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UNIT A5.3Dementia
The main clinical purpose of imaging in the setting of dementia has been and continues
to be the identification of treatable structural disease. However, as the population ages,
growing interest centers on understanding, characterizing, and potentially treating de-
menting illnesses. Although several types of imaging are applied, MRI is the most useful
structural imaging modality. In this unit, specific protocols intended to maximize the
contribution of MRI to the clinical evaluation of dementia are presented. Each protocol
has, as its foundation, a whole brain screen designed to evaluate for treatable causes of
dementia. Reflecting the frequent overlap of vascular disease with dementing illness, the
screening protocol also serves as an optimal evaluation of the patient with suspected
vascular dementia. Additional sequences or modifications are then used to answer specific
clinical questions. The evaluation of normal pressure hydrocephalus is reserved for a later
unit devoted to cerebrospinal fluid (CSF)-flow related diagnoses. The parameters given
here are derived from experience at 1.5 vT and may need to be altered slightly depending
on the field strength and the equipment manufacturer.
BASIC
PROTOCOL 1
VASCULAR DEMENTIA
Evaluation for usual structural treatable causes of dementia is not a demanding imaging
problem. Indeed, one might argue that computed tomography (CT) would suffice for most
applications. However, even a limited and fairly brief MR study will better characterize
potential abnormalities and allow more sensitive detection of subtle lesions, such as
subcortical ischemic injury, which is common in this patient group and may be of clinical
consequence. Multiplanar imaging and improved sensitivity to blood products are addi-
tional advantages provided by MRI.
Table A5.3.1 lists the five sequences that comprise the basic screening protocol along with
five additional sequences used to address specific imaging issues. Table A5.3.2 lists the
hardware necessary to perform the procedure. Next, stepwise instructions for performing
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Table A5.3.1 Screening Protocol/Vascular Dementiaa
Type of weighting and sequence Imaging plane
1. Pilot scan (scout)    —
2. T1-weighted spin echo Sagittal
3. T2-weighted TSE/FSE Transverse
4. Fast FLAIR Transverse
5. T2*-weighted gradient echo Coronal
Additional sequences for specific dementia diagnoses:
Alzheimer’s evaluation
6. 3-D short TR T1-weighted gradient echo Oblique coronal
or
7. T1-weighted spin echo Oblique coronal
Huntington’s evaluation
8. 3-D short TR T1-weighted gradient echo Coronal
or
9. T1-weighted spin echo Coronal
Parkinson’s evaluation
10. Dual echo PD-weighted/T2-weighted CSE Transverse
aAbbreviations: TSE, turbo spin echo; FSE, fast-spin echo; FLAIR, fluid attenuated
inversion recovery; PD, proton density; CSE, conventional spin echo.
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the protocol are provided. The protocol is not terribly demanding of scanner hardware
and may be performed on any clinical system. Basic Protocol 1 generally requires 20 to
25 min.
Set up patient and equipment
1. Interview the patient to ensure that he or she has no contraindications such as cardiac
pacemakers or other implants containing ferromagnetic materials. Also be sure to
find out if the patient has any health conditions that may require the presence of
special emergency equipment or other precautions during the scanning procedure.
In general, standard screening forms are used for all patients scanned in a magnetic
resonance system (APPENDIX 1).
The presence of any ferromagnetic metals may be a health hazard to the patient when he
or she is inside the magnet, and will also affect the imaging. If in doubt as to the exact
composition of the items, it is best to exclude patients with any metal implants; see Shellock
and Kanal (1996) for a discussion of what implants may be safely scanned using magnetic
resonance.
Patients may be accompanied into the magnet room by a friend or family member, who can
sit in the room during the scan and comfort the patient as needed. This companion must
be screened as well to ensure the absence of loose metal objects on the body or clothing.
2. If the procedure is a research protocol, have the patient sign any necessary consent
forms.
3. Have the patient remove all jewelry and change into a gown to eliminate any metal
that might be found in clothing.
4. Have the patient wash off mascara or other makeup to avoid local tissue heating and
image artifacts.
5. Inform the patient about what will occur during the procedure, what he or she will
experience while in the magnet, and how to behave, including the following:
a. If earphones or headphones are used to protect the ears from the loud sounds
produced by the gradients, the patient will be asked to wear these, but will be able
to communicate with you at any time during the imaging.
b. The patient will be given a safety squeeze-bulb or similar equipment to request
assistance at any time (demonstrate how this works).
c. For good results, the patient should be instructed not to talk unless absolutely necessary
and to avoid or minimize swallowing and other movements during each scan—i.e.,
as long as the banging sounds continue. Between scans, talking and swallowing are
acceptable in most cases, but should be avoided when comparative positional studies
are being performed; the patient will be informed when this is the case.
d. Nevertheless, the patient may call out at any time if he or she feels it necessary.
Table A5.3.2 Equipment Parameters
Coil type Quadrature head coil
Gradient coil strength 25 mT/m or whatever the system permits
Cardiac gating No
Peripheral gating For safety only
Respiratory gating No
Respirator If required by patient
Oxygen If required by patient
Motion cushions Useful
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6. Have the patient lie onto the table. Set up any triggering devices or other monitoring
equipment that is to be used either before or just after the patient lies down.
7. Center the patient in the head coil. Make sure that the head and neck are constrained
to limit motion.
Generally, the patient’s head is fixed so that the head is horizontal (not tilted) and the neck
and head lie along the axis of the patient table; other positions may be appropriate
depending on the needs at hand.
8. If needed, place a pillow or other support under the knees to make the patient more
comfortable.
9. Use the centering light to position the patient’s nasion and put him or her into the
center of the magnet.
Once this step has been performed, so long as the patient does not move on the table, the
table itself can be moved and then replaced in the same position as before without
jeopardizing the positioning of one scan relative to another.
10. If the patient is unable to hold still, provide an appropriate sedative.
Sequence 1: Rapid three-plane positioning pilot
11. To validate the patient’s position, run the system’s pilot (or scout) scan to ensure
correct location of the head in three dimensions, using the imaging sequence given
in Table A5.3.3 or similar parameters.
This sequence usually consists of three orthogonal planes to allow localization. The images
are often also used later to determine where to place the saturation pulses and to set up
total coverage of the volume of interest.
If the pilot scan shows the patient’s head to be significantly off-center then it may be helpful
to reposition the patient and repeat the pilot scan.
Sequence 2: Sagittal T1-weighted spin echo
12. Using images generated in sequence 1, plan sagittal images to provide whole brain
coverage. Set the parameters as indicated in Table A5.3.4. Run sequence 2.
The scan is best positioned first on the transverse pilot scan. Some angulation may be
needed to provide for true sagittal anatomic imaging. The coverage provided should then
be checked on the sagittal scout. This sequence is used to accurately position subsequent
scans. It provides excellent visualization of midline structures.
Sequence 3: Transverse T2-weighted TSE/FSE
13. Use the sagittal T1-weighted image to position transverse scans. Set parameters as
given in Table A5.3.5. Run sequence 3.
The scan is positioned graphically to provide whole brain coverage. The slices should be
angled according to an institutional standard for transverse images. The authors recom-
mend using the “AC-PC” line as such a standard. See Figure A5.1.2. Here, the anterior
and posterior commissures are identified on the sagittal T1-weighted midline image. The
slices of all transverse scans are positioned parallel to a line drawn between the two
landmarks. The sequence provides excellent visualization of the whole brain.
Sequence 4: Transverse fast FLAIR
14. Set parameters for transverse fast FLAIR as indicated in Table A5.3.6. Run sequence 4.
The scan is positioned identically to sequence 3. The sequence provides superior demon-
stration of T2-weighted bright lesions, especially in the supratentorial compartment. The
suppression of bright CSF afforded by the FLAIR technique demonstrates lesions adjacent
to CSF that would otherwise be poorly visualized. Subtle subcortical ischemic injury is
optimally visualized. FLAIR also nicely demonstrates extra-axial fluid collections, such as
subdural hematomas, occasionally seen in this patient population.
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Sequence 5: Coronal T2*-weighted gradient echo
15. Set parameters as indicated in Table A5.3.7. Using sagittal T1-weighted images,
position coronal images orthogonal to transverse images using graphic prescription
for whole brain coverage. Run sequence 5.
This sequence is designed to provide sensitivity to blood products through exploitation of
their susceptibility effects. Punctate foci of hemorrhage as seen in amyloid angiopathy or
coating of brain surfaces with hemosiderin as seen in superficial siderosis may not be
detected without susceptibility weighting. Use of the coronal plane simplifies interpretation
of skull base susceptibility artifacts inherent to this sequence.
Table A5.3.3 Parameters for Pilot Scan (Scout)
Patient position Supine
Scan type Gradient echo
Imaging plane (orientation) 3 planes
Central slice or volume center Run initially at magnet isocenter
Echo time (TE) Minimum
Repeat time (TR) Minimum
Flip angle (FA) 20°
Fields of view (FOVx, FOVy) 300 mm, 300 mm
Resolution (∆x, ∆y) 1.17 mm, 1.56 mm
Number of data points collected (Nx, Ny) 256, 192
Display matrix (Dx, Dy) 256, 256
Slice thickness (∆z) 5 mm
Number of slices 3, one in each of 3 cardinal planes
Slice gap Not applicable
Number of acquisitions (Nacq) 1
Swap read and phase encoding No
Scan time ∼10 sec
Table A5.3.4 Parameters for Sagittal T1-Weighted Spin Echo
Patient position Supine
Scan type Spin echo
Imaging plane (orientation) Sagittal
Central slice or volume center Midline
Echo time (TE) 14 msec
Repeat time (TR) 600 msec
Flip angle (FA) 90°
Fields of view (FOVx, FOVy) 230 mm, 230 mm
Resolution (∆x, ∆y) 1.20 mm, 0.90 mm
Number of data points collected (Nx, Ny) 192, 256
Slice thickness (∆z) 5 mm
Number of slices 19–21
Slice gap (distance factor) 1.5 mm (0.30)
Number of acquisitions (Nacq) 1
Read direction Cranio-caudal
Saturation pulses Inferior may be used
Scan time ∼2 min
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Table A5.3.5 Parameters for Transverse T2-Weighted TSE/FSE
Patient position Supine
Scan type TSE/FSE
Imaging plane (orientation) Transverse
Central slice or volume center Position for whole brain coverage
Echo time (TE) 85 msec
Echo train length (ETL) 5 to 8
Repeat time (TR) 2500 to 3000 msec
Flip angle (FA) 90°
Fields of view(FOVx, FOVy) 180 mm, 230 mm
Resolution (∆x, ∆y) 0.94 mm, 0.90 mm
Number of data points collected (Nx, Ny) 192, 256
Slice thickness (∆z) 5 mm
Number of slices 23
Slice gap (distance factor) 1.5 mm (0.30)
Number of acquisitions (Nacq) 1–2
Read direction Anterior to posterior
Saturation pulses Inferior may be used
Scan time ∼1–4 min
Table A5.3.6 Parameters for Transverse Fast FLAIR
Patient position Supine
Scan type Fast FLAIR
Imaging plane (orientation) Transverse
Central slice or volume center Position for whole brain coverage
Echo time (TE) 105–140 mseca
Echo train length (ETL) 7–11
Repeat time (TR) 8000–10,000 mseca
Inversion time (TI) 2000–2400 mseca
Flip angle (FA) 180°
Fields of view (FOVx, FOVy) 180 mm, 230 mm
Resolution (∆x, ∆y) 0.94 mm, 0.90 mm
Number of data points collected (Nx, Ny) 192, 256
Slice thickness (∆z) 5 mm
Number of slices 23
Slice gap (distance factor) 1.5 mm (0.3)
Number of acquisitions (Nacq) 1
Read direction Anterior to posterior
Saturation pulses Inferior may be used
Scan time ∼2.5–5 min
aOptimum choice of parameters for fast FLAIR varies significantly with manufacturer and scanner
limitations. For a review of parameter optimization in fast FLAIR, please refer to Rydberg et al. (1995).
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BASIC
PROTOCOL 2
ALZHEIMER’S DISEASE
Routine MRI scans nicely depict atrophy of mesial temporal lobe structures that suffer
the dominant impact of Alzheimer-type degenerative changes. In this protocol, an angled
T1-weighted sequence to provide a cross-section of hippocampal structures is chosen to
demonstrate these changes (Fig. A5.3.1). Multiple investigators employ a 3-D, short TR,
T1-weighted gradient echo sequence for sophisticated volumetric studies on Alzheimer
disease (AD) patients. Such a sequence is recommended in addition to the screening
protocol (see Basic Protocol 1) as an AD focused exam. Alternatively, a coronal T1-
weighted spin echo sequence will suffice when visual inspection only is planned.
Compared to the 3-D volume sequence, the 2-D spin echo sequence has the advantages
of being somewhat shorter in duration and overall less vulnerable to motion degradation.
Set up patient and equipment
1. Use the same equipment and perform patient setup as in Basic Protocol 1, steps 1 to 10.
2. Perform sequences 1 to 5 as described in Basic Protocol 1.
Sequence 6: Additional sequence for AD: 3-D oblique coronal short TR T1-weighted
gradient echo
3. Set parameters as indicated in Table A5.3.8. The scan is positioned graphically by
first locating the hippocampus on an off-midline slice from the sagittal T1-weighted
sequence (Fig. A5.3.2). Then position the volume for the current sequence so that the
plane of acquisition is orthogonal to the axis of the hippocampus. If the hippocampus
proves difficult to identify, then as a fall back approach, one may position the scan
to be parallel to the axis of the brainstem—this is usually a very similar plane as that
chosen directly orthogonal to the axis of the hippocampus. Run sequence 6.
This sequence demonstrates anatomy of mesial temporal lobe structures allowing for
optimal identification of the disproportionate atrophy seen in AD. The 3-D technique
employed provides thin slices and allows for reformations in additional planes.
Table A5.3.7 Parameters for Coronal T2*-Weighted Gradient Echo
Patient position Supine
Scan type 2-D gradient echo
Imaging plane (orientation) Coronal
Central slice or volume center Position for whole brain coverage
Echo time (TE) 20–25 msec
Repeat time (TR) 600–900 mseca
Flip angle (FA) 20°
Fields of view (FOVx, FOVy) 180 mm, 230 mm
Resolution (∆x, ∆y) 0.94 mm, 0.90 mm
Number of data points collected (Nx, Ny) 192, 256
Slice thickness (∆z) 4–6 mm
Number of slices 19–21
Slice gap 1–2 mm
Number of acquisitions (Nacq) 1–2
Read direction Cranio-caudal
Saturation pulses Inferior may be used
Scan time ∼2–6 min
aManufacturers vary in the efficiency of multiplanar slice acquisition in this sequence. Choice of TR and
slice thickness amounts to a trade-off between imaging time and resolution.
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Figure A5.3.1 A coronal T1-weighted image demonstrates disproportionate atrophy of mesial
temporal lobe structures, most notably the hippocampus (hi). Parahippocampal gyrus is also
marked (PHG).
Table A5.3.8 Parameters for Sequence 6: 3-D Oblique Coronal T1-Weighted
Patient position Supine
Scan type 3-D gradient echo
Imaging plane (orientation) Oblique coronal
Pulse sequence database SPGR
Central slice or volume center Temporal lobe
Echo time (TE) “Minimum full” (∼6 msec)
Repeat time (TR) 33 msec
Flip angle (FA) 35°–45°
Fields of view (FOVx, FOVy) 165 mm, 220 mm
Resolution (∆x, ∆y) 1.15 mm–0.86 mm, 0.86 mm
Number of data points collected (Nx, Ny) 144–192, 256
Slice thickness (∆z) 1.61 mm
Number of slices 124
Slab thickness 200 mm
Slice gap 0 mm
Number of acquisitions (Nacq) 0.75a
Read direction Cranio-caudal (superior to inferior)
Saturation pulses Inferior may be used
Scan time 7.5–10 min
aRefers to 3⁄4-NEX imaging, also known as partial Fourier imaging—an option available on many clinical
scanners. Partial Fourier imaging reduces imaging time by exploiting the inherent symmetry of k-space;
essentially, fewer phase encoding steps are used to provide the same spatial resolution. The time saved is
at the expense of the signal-to-noise ratio.
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Figure A5.3.2 An off-midline sagittal T1-weighted image allows visualization of long axis of
hippocampus (along arrowheads). Oblique coronal T1-weighted images are positioned perpendicu-
lar to the hippocampal long axis.
Table A5.3.9 Parameters for Oblique Coronal T1-Weighted Spin Echo
Patient position Supine
Scan type Spin echo
Imaging plane (orientation) Oblique coronal
Central slice or volume center Position for whole brain coverage
Echo time (TE) 14 msec
Repeat time (TR) 600 msec
Flip angle (FA) 90°
Fields of view (FOVx, FOVy) 180 mm, 230 mm
Resolution (∆x, ∆y) 0.94 mm, 0.90 mm
Number of data points collected (Nx, Ny) 192, 256
Slice thickness (∆z) 5 mm
Number of slices 23
Slice gap (distance factor) 1.5 mm (0.30)
Number of acquisitions (Nacq) 1–2
Read direction Superior to inferior
Saturation pulses Inferior may be used
Scan time ∼2–4 min
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Sequence 7: Alternate additional sequence for AD: 2-D oblique coronal T1-weighted
spin echo
4. Set parameters as indicated in Table A5.3.9. The scan is positioned in a manner
identical to that described for sequence 6. Run sequence 7.
This sequence demonstrates anatomy of mesial temporal lobe structures allowing for
optimal identification of the disproportionate atrophy seen in AD.
BASIC
PROTOCOL 3
HUNTINGTON’S DISEASE
Characteristic pathologic abnormalities for Huntington’s disease consist of bilateral
atrophy of the caudate nucleus and putamen (together denoted striatum), often accompa-
nied by a moderate degree of gyral atrophy in the frontal and temporal regions. The striatal
atrophy is best demonstrated in coronal plane (Fig. A5.3.3). As with Alzheimer’s disease,
a coronal T1-weighted sequence is chosen for its superior demonstration of anatomy.
Unlike the AD evaluation, the sequence is positioned in routine coronal and not oblique
coronal orientation. Again, an option of 3-D, short TR, T1-weighted gradient echo or 2-D
T1-weighted spin echo is provided. Considerations regarding sequence choice are identi-
cal to those noted in Basic Protocol 2.
Set up patient and equipment
1. Use the same equipment and perform patient setup as in Basic Protocol 1, steps 1 to 10.
2. Perform sequences 1 to 5 as described previously.
Sequence 8: Additional sequence for Huntington’s disease: 3-D coronal short TR
T1-weighted gradient echo
3. Set parameters as indicated in Table A5.3.8 with orientation to be normal coronal.
The scan is positioned perpendicular to prior transverse sequences (sequences 3 and
4). Run sequence 8.
A B
Figure A5.3.3 Coronal T1-weighted images of two Huntington’s patients, (A) and (B), demonstrat-
ing caudatal atrophy seen with advanced disease. In the normal, the caudate head bulges into the
lateral aspect of the anterior horn of the lateral ventricles. Atrophy of the caudate head results in
loss of the usual medially oriented convex margin, which may become flattened or with increasing
atrophy, concave. Reproduced from D.H. Yock (1995) with permission from Mosby.
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Sequence 9: Alternate additional sequence for Huntington’s disease: 2-D coronal
T1-weighted spin echo
4. Set parameters as indicated in Table A5.3.9 with orientation to be normal coronal.
The scan is positioned perpendicularly to prior transverse sequences (sequences 3
and 4). Run sequence 9.
BASIC
PROTOCOL 4
PARKINSON’S DISEASE
Little in the way of structural abnormality is present in Parkinson’s disease. However,
subtle findings in the midbrain reflecting the loss of dopaminergic nigrostriatal neurons
from the pars compacta of the substantia nigra have been identified (Duguid et al., 1986;
Rutledge et al., 1987; Braffman et al., 1989; Olanow, 1992). These findings consist of
narrowing or smudging of the high signal regions separating the substantia nigra from the
red nucleus and are best demonstrated by a sequence providing some susceptibility
weighting (Fig. A5.3.4). A conventional dual echo PD-weighted/T2-weighted spin echo
sequence is chosen for this application.
Set up patient and equipment
1. Use the same equipment and perform equipment and patient setup as in Basic Protocol
1, steps 1 to 10.
Figure A5.3.4 Conventional T2-weighted spin echo demonstrates narrowing and smudging of
pars compacta (arrow) in Parkinson’s Disease. The pars reticulata (black arrowhead) of the
substantia nigra exhibits low signal secondary to mineralization. The red nucleus (white arrowhead)
is similarly recognized.
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2. Perform sequences 1 to 5 as described previously. The transverse T2-weighted
sequence TSE may be omitted to save time.
Sequence 10: Additional sequence for Parkinson’s disease: Transverse dual echo
PD-weighted/T2-weighted spin echo
3. Set parameters as indicated in Table A5.3.10. The scan is positioned in the routine
transverse plane—as done for sequence 3. Run sequence 10.
The sequence will require more scanning time than the FSE/TSE sequence. With the
T2-weighted coverage provided, the T2-weighted TSE becomes somewhat redundant and
may be omitted. A conventional spin echo sequence is chosen because it provides modest
susceptibility weighting allowing visualization of mineralizated areas of the substantia
nigra. A more heavily gradient echo sequence may result in some “blooming” of the iron,
thereby obscuring the adjacent high signal region whose narrowing is detected. Sequences
minimizing susceptibility effect (FSE/TSE) might suffice, however, their utility for this
application has not been documented in the literature.
COMMENTARY
Background Information
Expected marked increases in the number of
elderly magnify the need for improved evalu-
ation, understanding, and, if possible, treatment
of dementia. The world population >65 years
of age is anticipated to grow at an annual rate
of 2.4%, leading to estimates of 37 million
demented people worldwide by the year 2020
(Cooper, 1994). In the U.S., ∼5% of the popu-
lation >65 years of age has severe dementia
with estimates of ≥15% for the population >85
years (Evans et al., 1989). Alzheimer’s disease
is the most common cause of dementia account-
ing for over one half of all cases. Its financial
cost in the U.S. has been estimated at 60 billion
dollars annually (Adams et al., 1997). In one
series, the Alzheimer’s incidence rate was 123
cases per 100,000 yearly (Schoenberg et al.,
1987). Prevalence increases drastically with
age. Per 100,000 population, prevalence is
3200 in ages 70 to 79 years and 10,800 in
individuals >80 years (Adams et al., 1997).
Table A5.3.10 Parameters for Dual Echo PD-Weighted/T2-Weighted
Conventional Spin Echo
Patient position Supine
Scan type Conventional spin echo
Imaging plane (orientation) Transverse
Central slice or volume center Midbrain
Echo time (TE) 30 msec and 80 msec
Repeat time (TR) 2500 msec
Flip angle (FA) 90°
Fields of view (FOVx, FOVy) 180 mm, 230 mm
Resolution (∆x, ∆y) 0.94 mm, 0.90 mm
Number of data points collected (Nx, Ny) 192, 256
Slice thickness (∆z) 5 mm
Number of slices 20
Slice gap (distance factor) 1–1.5 mm (0.20–0.30)
Number of acquisitions (Nacq) 0.75a
Read direction Anterior to posterior
Saturation pulses Inferior may be used
Scan time ∼6 min
aRefers to 3⁄4NEX imaging, also known as partial Fourier imaging—an option available on many clinical
scanners. Partial Fourier imaging reduces imaging time by exploiting the inherent symmetry of k-space;
essentially, fewer phase encoding steps are used to provide the same spatial resolution. The time saved is
at the expense of the signal-to-noise ratio.
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Routine clinical imaging of demented pa-
tients may not be necessary depending on the
clinician’s level of confidence in the diagnosis.
In general practice, any uncertainty regarding
the diagnosis usually prompts performance of
either CT or MRI. Imaging is specifically rec-
ommended when focal signs or symptoms sug-
gest either underlying treatable disorder (e.g.,
subdural hematoma, hydrocephalus, tumor) or
the presence of co-existent pathology (e.g.,
stroke, hemorrhage; Larson et al., 1986; Hol-
lister and Boutros, 1991). Imaging is also rec-
ommended in the setting of acute onset or rapid
progression of dementia symptoms.
In the following, an attempt to present a
complete discussion of the imaging findings in
dementia will not be made. Rather, specific
imaging findings relevant to protocol issues
will be emphasized. For the interested reader,
several recent excellent reviews of neuroimag-
ing in dementia are available, including discus-
sions representing radiologic (Braffman, 2000)
and neurologic (Chawluk, 1999) perspectives.
Alzheimer’s disease
The gross pathologic appearance in AD con-
sists of variable atrophy of temporal, frontal,
and parietal lobes with some sparing of periro-
landic regions. In the past decade, much interest
has centered on use of quantitative MRI tech-
niques to measure volume of hippocampi and
other mesial temporal lobe (MTL) structures.
The interest in this specific region derives from
several observations. First, atrophy of MTL
structures has been observed early and more
extensively in AD patients (de Leon et al.,
1989). Second, recognizing the central role of
MTL structures in memory (Squire, 1992),
memory impairment is an early and severe
manifestation of AD. Finally, the anatomy of
this particular region lends itself to volumetric
analysis more readily than that of other AD
involved structures.
Techniques applied to evaluation of MTL
atrophy in AD range from visual inspection to
sophisticated volumetric quantification. Some-
what surprisingly, even simple visual inspec-
tion has some utility and has been shown to
support the diagnosis of AD (sensitivity 81%;
specificity 67%) versus control population, es-
pecially in groups with lower baseline atrophy
(subjects <75 years of age; Scheltens et al.,
1992). Barclay and colleagues (1992) applied
subjective evaluation of MRI to distinguish
patients with AD from those with multi-infarct
dementia or mixed diagnostic features yielding
reasonable specificity in diagnosing AD. Fri-
soni applied a series of linear measurements
relating to MTL structures in a group of patients
with mild to moderate AD (Frisoni et al., 1996).
A compound measure including temporal horn
and choroid fissure widths along with hippo-
campal height was 86% sensitive in discrimi-
nating patients with mild AD from controls. As
a logical next step, Jack et al. applied volumet-
ric measurement of MTL structures in an effort
to diagnose patients with the mildest form of
AD as indicated by Clinical Dementia Rating
scores (Jack et al., 1997). Volume measure-
ments of hippocampi were 72% sensitive (with
specificity 90%) in diagnosing patients with
very mild AD compared with controls.
More recent studies have attempted to iden-
tify individuals at risk for developing AD using
MTL atrophy measurements. Convit and col-
leagues studied patients with minimal cognitive
impairment (MCI), a clinically defined group
with mild memory and/or word finding defi-
ciency, 75% of whom progress eventually to
AD (Flicker et al., 1991; Convit et al., 1997).
Hippocampal volume measurements correctly
classified MCI subjects compared with nor-
mals 74% of the time. Similar results support-
ing the ability of hippocampal volume esti-
mates to identify individuals at risk for AD have
been published by other laboratories (Kaye et
al., 1997; Jack et al., 1999).
Huntington’s disease
Huntington’s disease (HD) is readily recog-
nized by the clinical triad of chorea, dementia,
and personality disorder along with family his-
tory reflecting its dominant inheritance pattern.
In questionable cases, genetic analysis is used
to identify the defective gene. Such evaluation
may even be applied in asymptomatic patients.
For this reason, imaging evaluation is now
rarely utilized in most centers.
Characteristic imaging findings have been
described that are quite apparent in advanced
cases (Fig. A5.3.3). Directly paralleling the
pathologic changes, imaging demonstrates pro-
nounced bilateral atrophy of the caudate and
putamen (Simmons et al., 1986). The caudatal
atrophy results in a characteristic loss of the
usual bulge of caudate head into the anterior
horn of the lateral ventricle. On MRI, signal
abnormalities have been described in the
striatum and may consist variably of either
decrease or increase in signal intensity (Sa-
voiardo et al., 1991). Diffuse cerebral atrophy,
especially of the frontal lobes, occurs in later
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stages of HD and correlates with cognitive
decline (Starkstein et al., 1992; Aylward et al.,
1998).
Volumetric techniques are useful in mild
cases and might potentially have some value in
monitoring response to therapy. Atrophy of the
putamen, as demonstrated by MRI, exceeds
that of the caudate in mild disease (Harris et al.,
1992). Decreased basal ganglia volume has
been shown to correlate with presence of the
gene for HD in asymptomatic subjects (Ayl-
ward et al., 1994). Additionally, greater rate of
basal ganglia atrophy has been shown to corre-
late with earlier symptom onset (Aylward et al.,
1997).
Parkinson’s disease
The diagnosis of Parkinson’s disease rests
on clinical observation including core findings
of expressionless face, paucity of voluntary
movement, and resting tremor among others.
On MRI, reflecting the pathologic hallmark of
loss of pigmented cells in the substantia nigra,
especially in the pars compacta, the width of
the pars compacta is narrowed relative to con-
trols (Fig. A5.3.4; Duguid et al., 1986). The
observed narrowing of the pars compacta pre-
sumably relates to neuronal loss or may other-
wise reflect iron deposition.
The diagnostic challenge in Parkinson’s dis-
ease is generally one of separating it from nu-
merous other Parkinsonian syndromes, includ-
ing progressive supranuclear palsy, corticobasal
degeneration and the various forms of multiple
system atrophy. Occasionally, imaging may be
helpful in this regard. It should first be noted
that the finding on proton density weighted
images of pars compacta narrowing is not useful
in this regard as it has been reported in other
Parkinsonian syndromes including striatonigral
degeneration and progressive supranuclear
palsy (Stern et al., 1989). Separate findings for
the specific Parkinsonian syndromes are occa-
sionally observed and may be useful. In progres-
sive supranuclear palsy (PSP), some, but not all,
patients exhibit focal atrophy/signal abnormal-
ity of superior colliculi and/or periadequeductal
regions (Fig. A5.3.5; Savoiardo et al., 1989), a
finding not seen in typical Parkinson’s patients.
The diagnosis of PSP can be confused with that
of corticobasal degeneration (CBD), especially
at disease onset because atypical presentations
are not uncommon and the clinical syndromes
may be incompletely expressed (Davis et al.,
1985; Bergeron et al., 1996). Soliveri and col-
leagues reviewed the cognitive and MRI find-
ings of these two clinically overlapping ill-
nesses. They found the MRI findings of mid-
brain atrophy in PSP and asymmetric fron-
toparietal atrophy in CBD to be the most useful
and consistent aids to clinical evaluation in
distinguishing the two diseases (Soliveri et al.,
1999).
The term multiple system atrophy refers to
the complex syndrome exhibiting various de-
grees of Parkinsonism (striatonigral degenera-
tion), ataxia (olivopontocerebellar degenera-
tion), and autonomic dysfunction (Shy-Drager
syndrome). Each of these disorders may occur
either in isolation or in combination. Nearly all
forms of multiple system atrophy exhibit focal
low T2-weighted signal in the putamen, de-
scribed as “slit-like” signal void (Fig. A5.3.6;
Savoiardo et al., 1989; Lang et al., 1994). The
signal loss is presumed due to iron deposition
related to neuronal degeneration and is best
demonstrated with the susceptibility weighting
afforded by a T2*-weighted gradient echo se-
quence. Signal loss in the putamen distin-
guishes patients with multiple system atrophy
from those with typical Parkinson’s disease and
age-matched controls (Olanow, 1992).
Olivopontocerebellar degeneration is charac-
terized by marked neuronal loss in inferior
olives, pons, and cerebellum. In advanced
cases, inspection of T1-weighted sagittal and
T2-weighted transverse images reveals marked
atrophy of pons and cerbellar cortex, findings
helpful in diagnosis (Fig. A5.3.7; Savoiardo et
al., 1990).
Structural lesions of a variety of etiologies
may result in a Parkinsonian syndrome. Toxic
diseases resulting in focal basal ganglia lesions
may be associated with Parkinsonism. Focal
bilateral necrosis of the basal ganglia may result
from carbon monoxide poisoning, cyanide poi-
soning, methanol intoxication, among others,
and all may be associated with Parkinsonism
(Ley and Gali, 1983; Carella et al., 1988; Mess-
ing and Storch, 1988; Verslegers et al., 1988;
Rosenberg et al., 1989; Lee and Marsden, 1994;
Choi and Cheon, 1999; Sohn et al., 2000).
Metabolic disorders resulting in dense basal
ganglia calcification such as hypoparathyroid-
ism and pseudohypoparathyroidism may be
associated with various movement disorders
related to compromised function of the calci-
fied nuclei (Pearson et al., 1981). Parkinsonism
may be an unusual manifestation of hydro-
cephalus including both obstructive causes and
as a component of normal pressure hydro-
cephalus (Miodrag et al., 1987; Curran and
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Figure A5.3.5 Patient with progressive supranuclear palsy. Characteristic focal marked atrophy
of the superior colliculi (black arrows) and periaqueductal region (white arrowheads) is present.
Figure A5.3.6 Patient with striatonigral degeneration. T2-weighted coronal image demonstrates
slit-like signal void in putamen (large arrows) resulting from iron depostion. In this case, some high
signal was also seen adjacent to the patient’s left putamen (small arrows).
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Lang, 1994; Friedman, 1996; Krauss et al.,
1997). Even multiple deep grey infarcts may
result in Parkinsonism (Zijlmans et al., 1995).
Critical Parameters and
Troubleshooting
Motion artifacts may be a problem for nearly
any MRI examination and can be particularly
problematic in the population evaluated for
dementia. As always, proper care in placing and
securing the patient in the head coil is critical
as is the interaction of the MRI technologist
with the patient. In cases in which such meas-
ures are insufficient, prudent conscious seda-
tion should be employed if at all possible. If
sedation fails or is not possible, then faster
imaging may be considered. As a first step, the
provided sequences may be shortened simply
by reducing the acquisition matrix (Nx, Ny).
Fast imaging techniques do exist and will be
described in a later unit. However, such tech-
niques are particularly limited in matters of
A
B C
Figure A5.3.7 Profound atrophy of pons and cerebellum demonstrated by T2-weighted transverse (A) and T1-weighted
sagittal, midline (B) and para-midline (C) in this patient with olivopontocerebellar degeneration as a component of multiple
system atrophy.
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contrast and so may poorly demonstrate sub-
cortical ischemic injury and focal (especially
deep gray matter) atrophy.
Proper contrast in fast FLAIR imaging is
important to the dementia protocol. As noted
previously, manufacturers vary in their imple-
mentation of this sequence, including the pa-
rameters employed. Utilization of FLAIR
should begin with the manufacturer’s standard
parameters. Beyond this, some modifications
may yield more appealing images with im-
proved T2-weighted lesion contrast. Use of a TR
that is too low (i.e., <7000 msec) compromises
both T2-weighted contrast and CSF suppres-
sion. The TE should be fairly long, at least 100
msec, again for reasons related to T2-weighted
contrast. The inversion time (TI) is dictated by
the T1 of CSF and for a 1.5-T magnet should be
between 2200 and 2400 msec. The reader is
referred to Rydberg et al. (1995) for a thorough
discussion of the considerations involved.
The choice of TE in the T2*-weighted se-
quence affects sensitivity to blood products.
The use of a longer TE allows more time for
spin dephasing thereby enhancing detection of
small areas of old blood. In some ways, this
choice reflects a trade-off between increasing
sensitivity to old blood and reducing distracting
skull base susceptibility artifacts. The use of
coronal plane for this sequence is designed to
limit uncertainty in recognition of skull base
artifacts. The recommended TE range of 20 to
25 msec is empirically derived. Susceptibility
effects are strongly related to magnetic field
strength and are significantly decreased even at
1.0 T compared to 1.5 T. Use of longer TE at
lower field strengths will only partially com-
pensate for the reduced susceptibility effect.
Anticipated Results
The exam should provide full imaging char-
acterization of brain parenchymal lesions in-
cluding cortical and subcortical infarctions,
encephalomalacia, as well as diffuse and focal
atrophy. To accomplish this end, several types
of sequences with various T1, T2, and suscepti-
bility weighting are employed, including T1-
weighted spin echo, fast FLAIR, T2-weighted
FSE or CSE, and T2*-weighted gradient echo.
Each of these is performed in the plane in which
it is most helpful. The coronal T2*-weighted
gradient echo sequence optimally demon-
strates the hemorrhagic nature of lesions and in
doing so may illuminate the diagnosis. The
addition of a sequence in the coronal plane
better demonstrates the location of some le-
sions and is particularly helpful in charac-
terizing encephalomalacia related to prior
trauma.
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